Daniel Zabrowski

Daniel Zabrowski is the founder of M2SC Consulting LLC.
Current positions include Executive Chairman at Nimble Therapeutics, Inc. since 2019, Director at Omniome LLC, Independent Director at Endogena Therapeutics, Inc. since 2018, Director at Apexigen America, Inc. since 2014, Independent Director at Coagulo Medical Technologies, Inc., Independent Director at Actuate Therapeutics, Inc. since 2021, Director at AccuraGen, Inc. since 2013, Director at Ariagen, Inc. since 2018, and Venture Partner at Decheng Capital LLC since 2016.
Former roles include Director at Chugai Pharmaceutical Co., Ltd., Associate Director at Fujisawa Healthcare, Inc. in 1993, Executive Director-Drug Regulatory Affairs at Syntex (USA), Inc. in 1995, Director at Exosome Diagnostics, Inc., Independent Director at BeyondSpring, Inc. from 2020 to 2022, Director at Encodia, Inc., Independent Director at Apexigen, Inc. from 2016 to 2023, Head-Roche Sequencing Solutions at Roche Holding AG from 2013 to 2016, President-Roche Sequencing Unit at Ventana Medical Systems, Inc., Manager-Regulatory Affairs at G.D.
Searle LLC, Global Head-Drug Regulatory Affairs at Roche Pharma (Schweiz) AG from 1994 to 2016, and President at Roche Sequencing Solutions, Inc. Education includes a doctorate from Indiana University conferred in 1987 and undergraduate studies at St. Louis University.